Table 1.
Patient Demographics and Outcomes
| Patient study number |
Sex (M/F) |
Ethnicity | Age | Type of Cancer |
Active Disease Sites |
Stage | Number of TCR transgenic cells |
IL-2 doses | DC doses | Evidence of transient tumor response |
Response at EOS (day 90) |
PFS (mo) |
OS (mo) |
Current Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| F5-1 | M | Caucasian | 60 | Melanoma | Lung, Stomach, Liver, Pancreas, Peritoneum, Soft tissues | M1c | 1 x 109 | 12/14 | 3/3 | Yes by PET/CT | PD | 3 | 5 | Died of disease |
| F5-3 | M | Caucasian | 61 | Melanoma | Lung, Liver | M1c | 1 x 109 | 13/14 | 3/3 | Yes by PET/CT | SD | 7 | 86 | Died of disease |
| F5-6 | M | Caucasian | 59 | Melanoma | Lung, LN | M1b | 1 x 109 | 13/14 | 3/3 | Yes by PE | SD | 3 | 4 | Died of disease |
| F5-7 | M | Caucasian | 48 | Melanoma | SC, Bone | M1c | 1 x 109 | 9/14 | 3/3 | Yes by CT | SD | 4 | 11 | Died of disease |
| F5-8 | M | Caucasian | 44 | Melanoma | LN, Liver | M1c | 1 x 109 | 11/14 | 3/3 | Yes by PET/CT | SD | 4 | 11 | Died of disease |
| F5-9 | F | Caucasian | 46 | Melanoma | Skin, LN | M1a | 1 x 109 | 11/14 | 3/3 | No | PD | 3 | 20 | Died of disease |
| F5-12 | M | Caucasian | 40 | Melanoma | Lung, LN | MIVb | 3.9 x 109 | 6/9 | 3/3 | Yes by PET/CT | SD | 5 | 8 | Died of disease |
| F5-13 | M | Caucasian | 60 | Melanoma | Lung, Abdomen, SC | MIIIb | 4.41 x 109 | 4/9 | 3/3 | Yes by PET/CT | SD | 3 | 8 | Died of disease |
| ESO-1 | M | Hispanic | 47 | Liposarcoma | Right Renal Fossa; Liver left Lobe; Hepatic Segment; Peritoneal, Perihepatic Nodule | IV | 7.7 x 108 | 28/28 | 3/3 | No | PD | 2.6 | 16 | Died of disease |
| ESO-3 | F | Caucasian | 24 | Synovial Sarcoma | Right Lung; Multiple pulmonary Nodules | IV | 1 x 109 | 19/28 | 1/3 | Yes by PET/CT | PR | 67 | 67 | Alive with CR |
| ESO-4 | M | Caucasian | 41 | Synovial Sarcoma | Left Infraclavicular Mass; Left Pectoralis Mass | III | 1 x 109 | 18/28 | 3/3 | Yes by PET/CT | PD | 3 | 25 | Died of disease |
| ESO-5 | F | Caucasian | 43 | Synovial Sarcoma | Right popliteal fossa; Lung | IV | 1 x 109 | 14/14 | 3/3 | Yes by PET/CT | PR | 9 | 41.5 | Died of disease |
| ESO-6 | M | Caucasian | 26 | Osteosarcoma | Lung | IV | 1 x 109 | 14/14 | 3/3 | Yes by PET/CT | PD | 2.5 | 19 | Died of disease |
| INY-2 | M | Caucasian | 66 | Melanoma | LN, Liver | IV | 1 x 109 | 21/28 | 2/3 | Yes by PET/CT | PD | 3 | 6 | Died of disease |
| INY-3 | F | Caucasian | 44 | Synovial Sarcoma | Right popliteal fossa; Lung | IV | 1 x 109 | 14/14 | 3/3 | Yes by PET/CT | PD | 3 | 31 | Died of disease |
| INY-4 | M | Hispanic | 24 | Melanoma | Lung, LN, adrenal gland, liver, trachea, brain | IV | 1 x 109 | 10/14 | 3/3 | No | PD | NA | 3 | Died of disease |
Abbreviations: F: female; LN: lymph nodes; M: male; PFS: progression-free survival; OS: overall survival; EOS: end of study; DC: dendritic cells; TCR: T cell receptor; IL-2: interleukin-2; mo: months